Upload
thomas-wellner
View
1.381
Download
3
Tags:
Embed Size (px)
DESCRIPTION
Biomanufacturing Services / Contract Manufacturing Biologicals
Citation preview
1
BioContact Presentation | Fall 2008www.therapurebio.com
2
13/ of all newproducts
The future of medicine
2
3
$51B
$87B
$25B
$89B
2001
Protein therapeutic market
2005 2010 2010
Worldwide mobile technology market
4
You discovered a protein with blockbuster potential
Specific
Safe
Targeted
Efficacious
Novel
4
5
Ultimately, to get your product approved you will invest…
You are working hard to develop it
5
11 years 5 clinical trials 2,000 patients 39 patents ~$1 billion
66
What about manufacturing?
What about manufacturing?
7
Discovery Development
Marketing Manufacturing 7
8
Scaling up is not easy
Simple
Quick
Inexpensive
Milligrams
commercialbench
Complex
Long lead times - 4-5 years
Expensive -
$150+ million
Kilograms
8
9
Therapure Biopharma:Overcoming the manufacturing barrier
Complex We know protein purification
Long lead times Ready to go now
Quality cGMP compliant
Expensive Established Meadowpine Facility
Regulated We have 8 INDs under our belts
9
10
your trusted partneryour trusted partner
10
for protein manufacturin
g
for protein manufacturin
g
1111
Therapure Biopharma Focus
Provide clients accessto our biomanufacturing capabilities
– Product development– Protein purification – Cell culture– Formulation– Fill– Lyophilization – Finishing
Advance our pipeline• TBI 301
Post-liver transplant & acute and chronic HCV
• TBI 302 Hepatocellular carcinoma & metastatic colorectal cancer
• TBI 303 Proprietary protein modification technology
• TBI 304 Chemotherapy-induced anemia
1212
Experienced Management Team
• Thomas Wellner President and CEO
• Dirk AlkemaVice President, Operations
• Peter Winkley Vice President Finance and Chief Financial Officer
• David Bell Vice President, Drug Development and Chief Scientific Officer
13
About Us
Therapure Biopharma Inc. Canadian-based privately held biopharmaceutical company wholly owned by Catalyst Fund Limited Partnership II and management.
Catalyst Fund Limited Partnership IIA private equity fund with over $1B U.S. in capital that is managed by The Catalyst Capital Group Inc., a Toronto based private equity fund manager.
1414
Ideally located
15
90 minute flight to
60% of the U.S. population15
16
Our Unique and Flexible
Biomanufacturing Facility
16
17
130,000 square feet
5,700 sq.ft. of research laboratories
6,300 sq.ft. of QC labs
30,000 sq.ft. clean room manufacturing
28,000 sq.ft. controlled cGMP warehouse
2,200 sq.ft. GMP clinical pilot suites
18
Large Volume Protein Purification
18
19
Large Scale Processing Capabilities
19
20
Large Volume Storage Capacity
20
21
Central Service Chase
21
22
CIP Units For Process Equipment
22
23
Water For Injection
23
24
Purified Water System
24
25
Clean Rooms and Access Pointsto Meet cGMP Requirements
25
26
QC Laboratories
26
27
Sterile Fill Suite
27
28
Support Beyond Manufacturing
28
29
Biomanufacturing In-licensing Equity partnerships
• Late-stage products
• Approved products in new indications
• Possible targeted investment
Joint development• Innovative financing
• Product co-development
• Process development
• Formulation
• Protein purification
• Fill & finishing
Fee for service
Enhanced partnerships
29
30
Therapure(manufacturing)
Therapure(finance)
$$ (seed capital)
$$ (development fees)
protein product
interest/options
30
Biotech
Equity Partnership
30
31
partnership
Biotech
Therapure Biopharma
Product IP/development
Manufacturing IP/development
31
Joint Development
31
32
Therapure Biopharma Inc.
• Unique and Flexible– Scale of production– Range of production
• Expertise– Scientific– Manufacturing– Regulatory
• Financing opportunities
3333
LetLet
bring your biopharmaceutical to the world!
bring your biopharmaceutical to the world!
www.therapurebio.com